Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease

被引：52

作者：

Soroosh, Artin ^{[1
]}

Koutsioumpa, Marina ^{[1
]}

Pothoulakis, Charalabos ^{[2
]}

Iliopoulos, Dimitrios ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Ctr Syst Biomed, 650 Charles E Young Dr S,CHS 44-133, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Vatche & Tamar Manoukian Div Digest Dis, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90095 USA

来源：

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2018年 / 314卷 / 02期

基金：

美国国家卫生研究院;

关键词：

antisense therapeutics; chemical modifications; inflammatory bowel disease; microRNA; MODIFIED ANTISENSE OLIGONUCLEOTIDES; ULCERATIVE-COLITIS; CROHNS-DISEASE; INTESTINAL INFLAMMATION; RNAI THERAPEUTICS; DOWN-REGULATION; EXPRESSION; CHALLENGES; CANCER; PATHOGENESIS;

D O I：

10.1152/ajpgi.00268.2017

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Inflammatory bowel diseases (IBD) are chronic inflammatory gastrointestinal diseases, primarily consisting of ulcerative colitis and Crohn's disease. The complex nature of the disease, as well as the limited therapeutic options characterized by low efficiency and major side effects, highlights the importance of developing novel strategies of therapeutic intervention in IBD. Susceptibility loci related to IBD are present only in a small percentage of IBD patients, implying that epigenetic modifications could influence the pathogenesis of the disease. MicroRNAs (miRNAs) are small noncoding RNAs that regulate multiple molecular pathways involved in IBD pathobiology. MiRNA inhibitors targeting the IBD-activated miRNAs could have therapeutic value for IBD patients. This review provides an overview of the recent advances in miRNA biology related to IBD pathogenesis and the pharmacological development of miRNA-based therapeutics.

引用

页码：G256 / G262

页数：7

共 50 条

[31] The therapeutic potential of histamine receptor ligands in inflammatory bowel disease
Neumann, Detlef
Seifert, Roland
BIOCHEMICAL PHARMACOLOGY, 2014, 91 (01) : 12 - 17
[32] Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
Moon, Won
Park, Jae Jun
KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (06) : 233 - 242
[33] Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
Dostie, Kristen E.
Thees, Amy V.
Lynes, Michael A.
CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (27) : 3155 - 3161
[34] Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease
Batra, Suruchi K.
Heier, Christopher R.
Diaz-Calderon, Lina
Tully, Christopher B.
Fiorillo, Alyson A.
van den Anker, John
Conklin, Laurie S.
INFLAMMATORY BOWEL DISEASES, 2020, 26 (10) : 1597 - 1606
[35] Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance
Hamilton, Matthew J.
Snapper, Scott B.
Blumberg, Richard S.
JOURNAL OF GASTROENTEROLOGY, 2012, 47 (01) : 1 - 8
[36] Therapeutic drug monitoring in inflammatory bowel disease
Jossen, Jacqueline
Dubinsky, Marla
CURRENT OPINION IN PEDIATRICS, 2016, 28 (05) : 620 - 625
[37] Emerging therapeutic options in inflammatory bowel disease
Yamamoto-Furusho, Jesus K.
Parra-Holguin, Norma N.
WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (48) : 8242 - 8261
[38] New therapeutic approaches in inflammatory bowel disease
Hodgson, HJF
NETHERLANDS JOURNAL OF MEDICINE, 1997, 50 (02) : S15 - S18
[39] Therapeutic drug monitoring in inflammatory bowel disease
Kopylov, Uri
Ben-Horin, Shomron
Seidman, Ernest
ANNALS OF GASTROENTEROLOGY, 2014, 27 (04): : 304 - 312
[40] The potential therapeutic role of vitamin D in inflammatory bowel disease
Boccuzzi, L.
Infante, M.
Ricordi, C.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (10) : 4678 - 4687

← 1 2 3 4 5 →